智通财经APP讯，永泰生物-B(06978)发布截至2025年12月31日止年度业绩，该集团取得其他收入2050.7万元，同比减少39.31%;研发开支1.33亿元，同比减少13.89%;公司拥有人应占亏损2.31亿元，同比增加23.47%;每股亏损0.42元。
EAL®属广谱抗肿瘤细胞免疫治疗产品，在癌症治疗的临床应用方面具有逾十年的往绩。EAL®为最初取自患者自体外周血中的T细胞经使用专利方法活化、扩增培育而成的制剂。产品以CD8+杀伤性T细胞为主要活性成分，其细胞表面标记为CD3分子。
于本公告日期，本集团已完成II期临床试验430名目标受试者的入组工作。EAL®于2025年3月获得附条件NDA申请受理。随后EAL®纳入中国优先审评审批名单。于本公告日期，本集团核心候选产品EAL®的附条件NDA申请正在由国家药监局药品审评中心审评中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.